

1

2 **Title: Naïve T lymphocytes chemotax to CCL21 but not to S1P-rich serum**

3

4 **Authors**

5 Nicolas Garcia-Seyda<sup>1,2</sup>, Solene Song<sup>1,2</sup>, Luc David-Broglio<sup>1</sup>, Christoph Matti<sup>3</sup>, Marc Artinger<sup>3,4</sup>,  
6 Martine Biarnes-Pelicot<sup>1</sup>, Marie-Pierre Valignat<sup>1</sup>, Daniel F. Legler<sup>3,5,6</sup>, Marc Bajénoff<sup>2</sup> and Olivier Theodoly<sup>1\*</sup>

7

8

9 **Affiliations**

10 <sup>1</sup> Aix Marseille Univ, Inserm, CNRS, Turing Center for Living Systems, LAI, Marseille, France.

11 <sup>2</sup> Aix Marseille Univ, Inserm, CNRS, CIML, Marseille, France.

12 <sup>3</sup> Biotechnology Institute Thurgau (BITg) at the University of Konstanz, Unterseestrasse 47, 8280  
13 Kreuzlingen, Switzerland.

14 <sup>4</sup> Graduate School for Cellular and Biomedical Sciences, University of Bern, 3012 Bern, Switzerland.

15 <sup>5</sup> Faculty of Biology, University of Konstanz, Universitätsstraße 10, 78464 Konstanz, Germany.

16 <sup>6</sup> Theodor Kocher Institute, University of Bern, Freiestrasse 1, 3012 Bern, Switzerland.

17

18 \* Correspondence to: [olivier.theodoly@inserm.fr](mailto:olivier.theodoly@inserm.fr)

## 19 **Summary**

20 Naïve T lymphocytes traffic through the organism in their search for antigen, alternating between blood and  
21 secondary lymphoid organs. Lymphocyte homing to lymph nodes relies on the chemokine CCL21, while exit  
22 into efferent lymphatics relies on the sphingolipid S1P. Surprisingly, while both molecules are claimed  
23 chemotactic, a quantitative analysis of naïve T lymphocyte migration along defined gradients is missing. Here,  
24 we used a reductionist *in vitro* approach to study the real-time, single-cell response of naïve T lymphocytes to  
25 CCL21 and S1P-rich serum. Using high-throughput microfluidic and optical micropatterning ad hoc tools, we  
26 show that CCL21 triggers long-range chemotaxis whereas S1P-rich serum does not. Instead, S1P-rich serum  
27 triggers a transient polarization that may represent a brief transmigration step through exit portals. Our data  
28 thus validate naïve T lymphocyte chemotaxis towards CCL21 but not S1P, which complements *in vivo*  
29 observations and is of interest for a better tailoring of immunosuppressive drugs.

## 31 **Keywords**

32 Leukocyte migration, CCL21, ICAM-1, S1P, lymph node traffic, adhesion, chemotaxis, haptotaxis,  
33 microfluidics, naïve T cells

## 35 **Introduction**

Chemokinesis: random migration triggered by a soluble cue.

Haptokinesis: random migration triggered by an adsorbed cue.

Chemotaxis: directed migration along a soluble cue shaped as a gradient.

Haptotaxis: directed migration along an adsorbed cue shaped as a gradient.

37  
38 Naïve T lymphocytes circulate through the organism in the search for cognate antigens, thereby alternating  
39 between secondary lymphoid organs (SLOs), lymphatics and the blood<sup>1</sup>. Entry to and homing within SLOs are  
40 dependent on the CCR7 receptor, present on lymphocytes, and its cognate ligand CCL21 produced by stroma  
41 cells in lymphoid tissues<sup>1,2</sup>. Egress from SLOs is in turn dependent on the S1PR1 receptor and its cognate  
42 ligand S1P, a small sphingolipid abundant in blood and lymph<sup>3</sup>. The lymphocyte transit time through lymph  
43 nodes is thus controlled by a balance between CCL21-controlled recruitment and retention, and S1P exit  
44 signals<sup>4</sup>. For this reason, disruption of the S1PR1-S1P signaling axis represents an immunosuppressing therapy  
45 applicable to a wide range of pathologies, including multiple sclerosis, transplant rejection, diabetes and  
46 cancer<sup>5,6</sup>. Surprisingly, while there is a general consensus that both CCL21 and S1P carry their functions  
47 through chemotaxis, a quantitative analysis of naïve T lymphocyte migration along defined CCL21 and S1P  
48 gradients is missing.

49 In the case of CCL21, lymph node gradients have been reported across organ peripheries: Across B cell  
50 follicles<sup>7</sup>, along interfollicular regions<sup>8</sup>, and along medullary cords<sup>9</sup>. All three increase in concentration  
51 towards the central parenchyma, suggesting a single and common source: the T cell zone. Due to its positively  
52 charged C-terminal tail, CCL21 interacts with and is retained by extracellular matrix (ECM) components such  
53 as heparan sulfate or collagen<sup>10-13</sup>. This capacity prevents it from being washed away during  
54 immunohistological sample preparation, allowing its visualization as a gradient, and it has been claimed that  
55 only such immobilized CCL21 triggers naïve T lymphocyte migration<sup>14</sup>. *In vivo*, chemotaxis of naïve T  
56 lymphocytes has only been recorded along medullary cords<sup>9</sup>. Other reports suggest instead random migration,  
57 at least in other regions of the lymph node<sup>15-18</sup>. However, a drawback of *in vivo* experiments is that they cannot  
58 prove whether chemotaxis is triggered by a single visualized gradient or by additional yet unspecified gradients.  
59 For instance, CCL19 is another homeostatic CCR7 ligand present in lymph nodes and triggering naïve T  
60 lymphocyte chemotaxis *in vitro*<sup>19</sup>, but its distribution *in vivo* remains unknown because it does not bear a  
61 ‘sticky’ tail and does not become immobilized<sup>20</sup>. Since T cell zone stromal cells simultaneously produce  
62 CCL19 and CCL21<sup>21,22</sup>, both chemokines are necessarily overlapping, making it difficult to judge which one  
63 is guiding naïve T lymphocytes *in vivo*. Also, the fact that a chemokine may be simultaneously immobilized  
64 or soluble, coupled to the impossibility to reveal the soluble pool by staining, may further hinder the  
65 deciphering of traffic mechanisms. Such co-existences of immobilized and soluble chemokine pools have been  
66 demonstrated for the B cell zone chemokine CXCL13<sup>23,24</sup>. In the case of CCL21, Dendritic Cells (DCs) cleave  
67 its C-terminal tail transforming it into a soluble pool that triggers chemotaxis of these cells<sup>25</sup>, but has additional  
68 unique features as compared to the other CCR7 ligands<sup>26</sup>. In this context, a model of chemokine cloud was  
69 tentatively proposed in which molecules are trapped as local ‘soluble depots’ within the glycoocalix<sup>27</sup>.  
70 Regarding naïve T lymphocytes, it remains unclear to what extent CCL19 and CCL21 guide them *in vivo*, and  
71 whether CCL21 does it as a soluble or immobilized pool.

72 For S1P, the perspective is even more complex due to its pleiotropic functions, and since its soluble and lipidic  
73 nature impairs molecular labeling and gradient visualization. An elegant tool was recently developed in which  
74 S1P presence is deduced from the internalization rate of its receptor, which allowed for gradient identification  
75 in the spleen<sup>28</sup>. However, while the same authors reported higher S1P concentrations in lymph node medullary  
76 cords than in the T cell zone, they failed to detect a gradient within or between those two areas<sup>29</sup>. In addition  
77 to the lack of *in vivo* gradient identification, the percentage of naïve T lymphocytes responding *in vitro* to S1P  
78 is strikingly low, typically below 10%<sup>4,30-34</sup>. While it was claimed a consequence of its receptor’s fast  
79 desensitization, this number was recently increased to almost 20% when lymphatic endothelial cells (LECs)  
80 were added to the experiments<sup>35</sup>, consistent with those cells controlling a transmigration step towards S1P,  
81 rather than long-distance chemotaxis towards it. In the same line, other functions have been suggested for S1P

82 such as migration inhibition alone<sup>36</sup> or migration inhibition with modulation of adhesion<sup>37</sup>. Another report  
83 defends a stromal gate model where S1P acts mainly on LECs, to allow or block lymphocyte transmigration  
84 without otherwise affecting their migration<sup>38</sup>. Finally, an *in vivo* report revealed that naïve lymphocytes  
85 randomly approach cortical sinus exit points, with no apparent chemotaxis involved<sup>16</sup>. Altogether, while  
86 chemotaxis to S1P is the prevailing model for naïve T lymphocyte exit from lymph nodes, the standing  
87 evidence is conflicting.

88 Chemotaxis towards CCL21 and S1P remains to be faithfully demonstrated with a reductionist *in vitro*  
89 experiment where cells would migrate along a single, controlled gradient. However, the typical off-the-shelf  
90 tools in biology or immunology labs, the Transwell assays, do not properly and selectively probe chemotaxis.  
91 Transwell assays consist of two overlaid chambers, the top one containing cells and the bottom one the  
92 molecule being tested. The chambers are separated by a porous membrane through which cell transmigration  
93 is scored. While easy to handle, these assays offer no control over the gradient shape nor the moment of its  
94 arrival (time zero). They are an endpoint assay with no mechanistic insight due to the lack of *live* imaging,  
95 score transmigration through a 10-50  $\mu\text{m}$  thick porous membrane without information on longer-distance  
96 gradients, and in the absence of proper controls are unable to distinguish effects of transmigration,  
97 chemokinesis or chemotaxis<sup>39</sup>. Moreover, in the case of S1P such controls are uninformative due to the fast  
98 receptor desensitization, which precludes coincubating the molecule with the cells in the upper chamber.

99 The uncertainty on CCL21 and S1P guiding properties would be finally solved with *live* imaging, accessible  
100 with microfluidic tools. However, microfluidic devices for gradient generation are generally based on flow or  
101 do not control residual drifts, therefore washing away weakly or non-adhesive cells. This is the case for naïve  
102 T lymphocytes, claimed to be non-adhesive on ICAM-1 unless subjected to mild shear stress<sup>14</sup>. To circumvent  
103 this caveat, we recently developed a microfluidic device for gradient generation in the absence of flow and  
104 used it to prove naïve T lymphocyte chemotaxis towards CCL19<sup>19</sup>. Here, we used high-throughput microfluidic  
105 and protein printing ad hoc approaches to dissect the response of naïve T lymphocytes to immobilized and  
106 soluble CCL21 and S1P-rich serum, at the single cell level. We first show that both adsorbed and soluble  
107 CCL21 trigger naïve T lymphocyte haptotaxis and chemotaxis, respectively, when presented as homogeneous  
108 chemokine fields. Next, we show that naïve T lymphocytes do adhere on ICAM-1 substrates, though in a weak  
109 and intermittent way which is not stabilized by shear stress. We finally demonstrate that CCL21 gradients  
110 trigger naïve T lymphocyte haptotaxis and chemotaxis, while under similar conditions S1P-rich serum does not.  
111 Serum triggers instead a transient polarization which is consistent with a short transmigration step, rather than  
112 a long-distance attraction.

113 Importantly, there is a long-standing call for better understanding the human immunology<sup>40,41</sup>. With most of  
114 the above-mentioned evidence arising from mouse models and a recent report indicating differences between


115 both species<sup>42</sup>, plus the numerous therapeutic opportunities expected from a better understanding of the S1PR1-  
 116 S1P signaling axis, we carry our studies on naïve T lymphocytes purified from healthy human donors.

117

## 118 Results

### 119 CCL21 triggers naïve T lymphocyte hapto- and chemo-kinesis

120 Based on *in vitro* live imaging, it has been claimed that CCL21 does not stimulate naïve T lymphocytes unless  
 121 adsorbed on a substrate<sup>14</sup>. Since our microfluidic device creates soluble gradients based on diffusion, we first  
 122 tested whether CCL21 triggered migration of human naïve CD4<sup>+</sup> T lymphocytes while in bulk solution only.  
 123 We analyzed the behavior of cells in non-adherent single channels either coated with the chemokine, rinsed  
 124 and blocked with BSA (Fig 1A, adsorbed CCL21), or coated with pluronic F127, which keeps the chemokine  
 125 and cells in solution<sup>43</sup> (Fig 1B, bulk CCL21). We observed cell polarization and random migration in both  
 126 conditions, demonstrating the molecule's hapto- and chemo-kinetic potential (Fig 1 and Movie 1). To verify  
 127 that CCL21 had not permanently adsorbed (immobilized) on the F127 substrate, the channel was rinsed at the  
 128 end of the experiment and fresh cells were added. We observed only 2% migrating cells, proving that the  
 129 chemokine had been rinsed and thus suggesting that the observed effect was triggered from molecules in the  
 130 bulk solution. Based on these results, we conclude that CCL21 triggers efficient cell migration when presented  
 131 in solution, and therefore can be used in our microfluidic device for studying naïve T lymphocyte chemotaxis.  
 132 In addition, migration in the absence of adhesion reveals the swimming capacity of naïve T lymphocytes, as  
 133 previously reported for effector T lymphocytes, amoeba and neutrophils<sup>43-45</sup>.



134

135 **Fig 1. CCL21 triggers hapto- and chemo-kinesis of naïve T lymphocytes.** Top row, bright field 10-minute time projections of cells in the presence (+) or absence  
 136 (-) of CCL21 adsorbed on BSA (A, haptokinesis) or kept in bulk solution over an antifouling F-127 substrate (B, chemokinesis). Bottom, Quantification of cell  
 137 polarization in each condition and trajectories aligned in the origin for cells tracked over a 16-minutes period, in the presence (colored lines, > 500 tracks are shown)  
 138 or absence (overlaid in black, > 500 tracks are shown) of chemokine. For the last condition, bulk CCL21 was rinsed (R) and fresh cells were added to detect potentially  
 139 adsorbed chemokine. Data is from one representative donor, nBSA = 2, nF127 = 3 donors. Scalebar = 30μm. (C) Cartoon description as used in all subsequent figures,  
 140 describing stimulus nature and substrate color-code. The dotted frames represent the limits of the experimental chamber, from a transversal viewing point.


## 141 **Naïve T lymphocytes intermittently adhere on ICAM-1**

142 It has also been claimed that naïve lymphocytes do not adhere on ICAM-1 in the absence of shear stress<sup>14</sup>.  
143 However, when we imaged cells in single channels coated with ICAM-1 and CCL21 we noted that they  
144 explored a greater surface area (Fig 2A and Movie 2). Instant speed analysis revealed two populations on  
145 ICAM-1 substrates: one of low speed, equal to that of cells in the absence of adhesion, and one of higher speed,  
146 likely corresponding to cells adhering on the ICAM-1 (Fig 2B). We therefore performed Interference  
147 Reflection Microscopy (IRM) to characterize such populations. With this imaging technique, cells in close  
148 contact to the substrate display destructive optical interference leading to an intensity darker than the  
149 background, whereas non-adherent cells present constructive optical interference leading to a brighter  
150 intensity. While cells migrating on BSA barely presented adhesion fingerprints, cells on ICAM-1 sequentially  
151 alternated between adherent and non-adherent states (Fig 2C). Single cell analysis of instant speed and adhesion  
152 area further revealed that temporal adhesion is indeed a prerequisite for fast migration (Fig 2C). Intermittent  
153 adhesion did not arise from a shortage of adsorbed chemokine since similar results were obtained when the  
154 chemokine was kept in bulk solution, at high concentration, over the ICAM-1 substrate (Fig 2D and Movie 3).  
155 Finally, application of a 0.2 dyn shear stress did not stabilize adhesion<sup>14</sup> but rather washed cells away, likely  
156 when switching into the swimming regime (Fig 2E and Movies 4 and 5). Based on these results, we conclude  
157 that naïve T lymphocytes do adhere on ICAM-1, though in an intermittent fashion which is not stabilized by  
158 shear stress nor chemokine availability.

## 159 **CCL21 gradients trigger naïve T lymphocyte hapto- and chemo-taxis**


160 Given that bulk CCL21 triggered naïve T lymphocyte chemokinesis, we next tested whether it also triggered  
161 their chemotaxis by using our microfluidic device for soluble gradient generation<sup>19</sup>. In our setup, cells are  
162 injected in a central channel and their behavior is recorded in response to a gradient established by diffusion  
163 (Fig 3A). Parallel channels on each side are used as the chemoattractant source and sink; they are separated  
164 from the central one by a double array of trapezoidal pillars holding permeable agarose barriers, which allow  
165 chemokine diffusion while dampening flow across them. A mild flow assures chemokine replenishment and  
166 removal at the source and sink channels, respectively, while the width of the central channel imposes the  
167 gradient steepness, with profiles spanning 500 to 1000  $\mu\text{m}$  in length<sup>19</sup>. When CCL21 was applied as a soluble  
168 gradient, we observed strong directional migration towards increasing chemokine concentrations (Fig 3B and  
169 Movie 6). However, because the chemokine adsorbs on various substrates (Fig 1 and 2), this effect could arise  
170 from a combination of the applied soluble gradient plus a potential haptotactic one building up during the  
171 experiment, due to molecules instantly captured on the substrate. We thus turned into self-made chemokine  
172 versions<sup>46</sup> to identify each contribution.

173



174

175 **Fig 2. Naïve T lymphocytes intermittently adhere to immobilized ICAM-1.** (A) Top row, bright field 5-minute time projection of cells in the presence (+) or  
 176 absence (-) of CCL21 adsorbed on ICAM-1. Scalebar = 30µm. Bottom, Quantification of cell polarization in each condition plus trajectories aligned in the origin for  
 177 cells tracked over a 16-minute period, in the presence (colored lines, >1000 tracks) or absence (overlaid in black, >1000 tracks) of chemokine. Data is from the same  
 178 donor as in Fig 1, nICAM-1 > 3 donors tested. (B) Instant speed distribution calculated over 1-minute intervals, for migrating cells in Fig 1 and 2A. n = 11709, 9256  
 179 and 5095 values calculated for ICAM-1, BSA and F127, respectively. (C) Left, overlaid bright field (grey) and inverted IRM (green = adhesion patch) time projections,  
 180 to reveal adhesion fingerprints while migrating on the indicated substrates. nICAM-1 > 3 donors tested. Scalebar = 10µm. Right, single cell analysis of instant speed  
 181 (over 1-minute intervals) and adhesion area for a representative cell on each substrate. (D) Overlaid bright field (grey) and inverted IRM (green = adhesion patch)  
 182 time projections for cells migrating on an ICAM-1 substrate with 1µg/ml CCL21 kept in bulk solution. Scalebar = 10µm. n > 3 independently tested donors. (E)  
 183 Percent of migrating cells remaining on ICAM-1 substrates with or without adsorbed CCL21 after addition of 0.2dyn flow. Each color represents an independently  
 184 tested donor. \*\* indicates a p-value < 0.01 in a multiple comparison ANOVA test.



185  
186 **Fig 3. CCL21 gradients trigger hapto- and chemo-taxis of naïve T lymphocytes.** (A) Left, overlaid bright field and fluorescent signal for an illustrative CCL21  
187 gradient at time zero and after 30 minutes of acquisition. For the later, bright field images were projected to highlight cell trajectories, the white circles indicating  
188 their final position. White arrows indicate flow direction in the side channels, replenishing the source and clearing the sink to keep them at maximum and minimum  
189 chemokine concentrations, respectively. Agarose barriers, held by trapezoidal PDMS pillars, allow chemokine diffusion while hampering fluid flow across the central  
190 channel. Fluorescent 10 Kda Dextran is used to verify gradient establishment and lack of flow. Scalebar = 100µm. Right, normalized gradient profiles taken at 1-



191 minute intervals, the color-code representing time from 0 to 30 minutes. Opaque PDMS pillars appear as fluorescent signal drops. Cells experience increasing  
192 concentrations of chemokine, ranging from 0 to 75% of the concentration at the source. (B) Trajectories aligned in the origin and angle histogram for a total of 55  
193 cells from one representative donor, tracked over 50 minutes. N = 4 donors tested. (C) Cartoon illustrating the calculation of the chemotactic index (C. I.) as a ratio  
194 between the net displacement along the gradient direction (d) and the trajectory length. Each value is then tagged with the local chemokine concentration (C) and  
195 slope ( $\Delta C$ ) over 10 $\mu$ m length, the typical body size for a naïve T lymphocyte. (D) Heatmap for the chemotactic Index (C.I.) as a function of  $\Delta$ CCL21 bulk concentration  
196 and gradient slope for 3 independently tested donors (n = 215 tracks, 6422 C.I. values calculated over 1-minute intervals). N.M. = Not Measured or below a threshold  
197 of 25 values. (E) Top, cartoon illustrating the subtractive printing protocol. Below, fluorescent image and profiles along the patterned area (ON pattern) or out of it  
198 (OFF pattern). Bottom, cell trajectories on the patterned area, color-coded with time over a 20-minute period. (F) Heatmap for the chemotactic Index (C.I.) as a  
199 function of chemokine substrate concentration and gradient slope for 3 independently tested donors (n = 6809 tracks, 7878 C.I. values calculated over 1-minute  
200 intervals). N.M. = Not Measured or below a threshold of 25 values.


201  
202 To determine the soluble contribution we used a truncated variant, CCL21<sup>24-102</sup> or  $\Delta$ CCL21, lacking the C-  
203 terminal basic motif and therefore expected to remain exclusively in bulk solution. Because its diffusion is  
204 represented by a similar weight FITC-Dextran tracer, fine analysis of Chemotactic Index (C.I.) versus gradient  
205 concentration and slope was achieved (Fig 3C). Chemotaxis was maximum at high slopes and 80-120 nM  
206 concentrations, but detectable from a 0.4% increment over a cell body-length (Fig 3D). To determine the  
207 haptotactic contribution, we then used a fluorescently labelled CCL21, CCL21-S6<sup>Dy549P1</sup>. Starting from a  
208 homogeneously adsorbed chemokine substrate as in Fig. 1A, we used a subtractive printing protocol<sup>47,48</sup> to  
209 degrade chemokine functionality and create patterns of interest in various slopes and intensity ranges (Fig 3E).  
210 Since leukocyte migration is biased by gradients of adhesion ligands<sup>47</sup>, we performed these experiments in the  
211 absence of adhesion. The fluorescent signal was then transformed into number of adsorbed molecules with the  
212 aid of a calibration curve (Supplementary fig. 1). When correlated to the calculated C.I. values, haptotaxis was  
213 identified at high slopes and 4-6 x 10<sup>4</sup> molecules/ $\mu$ m<sup>2</sup> (Fig. 3F). Based on these results, we conclude that  
214 CCL21 effectively triggers naïve T lymphocyte hapto- and chemo-taxis.

### 215 Serum modulates S1PR1 surface expression on naïve T lymphocytes


216 Naïve T lymphocytes are assumed to exit lymph nodes following a gradient of S1P. However, directed  
217 migration towards S1P was never imaged, neither *in vivo* nor *in vitro*. We therefore decided to challenge this  
218 idea using our microfluidic device. Due to its lipidic nature, S1P is carried in blood by albumin and  
219 apolipoprotein M, each of them having apparent distinct functions and cellular targets<sup>49,50</sup>. Those carriers are  
220 not yet elucidated for lymph, thus it is not known in which state naïve T lymphocytes encounter and sense S1P  
221 at cortical sinus exit points, which might explain the low transmigration values reported in the literature.  
222 Following this consideration, and since lymph is mixed with blood at the thoracic duct and both fluids trigger  
223 similar S1PR1 desensitization<sup>51</sup>, we tested autologous donor serum as the source of bioactive S1P. In this way,  
224 we also sought to reduce inter-donor variability due to the use of human cells. Because experiments in mice  
225 proved that S1PR1 desensitizes within minutes of exposure<sup>30</sup>, we first sought to characterize its dynamics in  
226 human cells. In agreement with the literature<sup>52</sup>, naïve T lymphocytes did not express S1PR1 when directly

227 stained in blood, though resensitization occurred during cell purification (Fig 4A). When incubated in the  
228 absence of fetal calf serum, cells remained viable (Supplementary fig. 2A) and S1PR1 expression reached a  
229 plateau with  $84 \pm 8\%$  resensitized cells (Supplementary fig. 2B). When resensitized cells were then exposed  
230 to autologous human serum, we observed a fast, concentration dependent S1PR1 desensitization within 5  
231 minutes (Fig 4B). These results thus validated serum as a source of bioactive S1P, which was used for  
232 subsequent experiments.

233



**Fig 4. Serum modulates S1PR1 surface expression on naïve T lymphocytes.** (A) S1PR1 live staining performed on whole blood cells, PBMC's and naïve T lymphocytes, along the purification process. Arrows indicate the gating strategy. (B) Left, S1PR1 modulation on cells exposed to 50% serum concentration and then fixed at the indicated timepoints. Right, S1PR1 modulation on cells exposed 5 minutes to the indicated serum concentrations and then fixed. Gray histograms correspond to isotype controls. Data representative from 1 out of 3 and 2 independently tested donors, respectively.




255

256

## 257 **Serum triggers transient polarization and chemokinesis of a fraction of cells, but not chemotaxis**

258 We first analyzed the response of resensitized cells to serum in single channels coated with ICAM-1. We  
259 observed a mild but significant effect for 10% serum concentration, with  $12 \pm 7\%$  polarizing cells (Fig 5A).  
260 IRM imaging proved migrating cells were intermittently adhering, ruling out the hypothesis of adhesion  
261 inhibition (Fig 5B and Movie 7). In addition, when cells were simultaneously exposed to both S1P-containing  
262 serum and CCL21, no apparent inhibition of cell migration nor adhesion was observed (Supplementary fig 3).  
263 In line with a faster receptor desensitization at high serum concentrations (Fig 4B), we observed only  $3.5 \pm 1\%$   
264 polarized cells with 90% serum concentration. Because many of the responding cells were already polarized  
265 when starting the acquisition, we assume the response occurred and was completed during cell sedimentation,  
266 typically few minutes long. This result highlights the importance of controlling and visualizing the instant of  
267 stimulus addition (time-zero), achievable only in controlled microfluidic setups.

268 We then exposed resensitized cells to controlled serum gradients in our microfluidic device. By visualizing the  
269 moment of serum arrival, we observed a slightly stronger effect than in single channels, with  $21 \pm 6\%$  cells  
270 polarizing upon serum arrival (Fig 5C). For many of them though the effect lasted few minutes, shortly  
271 polarizing on the spot without a net displacement (Fig 5D and Movie 8). Indeed, only 48 out of 620 imaged  
272 cells (7.7 %) displaced more than  $20 \mu\text{m}$  (2 body lengths) and were tracked (Fig 5E). Track duration was short,  
273 with a median of 11 minutes, therefore limiting cell displacement to  $100\mu\text{m}$  (Fig 5F and Movie 8). As a  
274 comparison, CCL21 tracks ended either when the cells reached the channel's upper limits or when the movie,  
275 typically 50 minutes long, was over. Migrating cells did not exhibit a marked directionality towards the serum  
276 source, albeit the distribution of C.I. values was slightly skewed towards it. Because our gradients are built by  
277 gradual arrival of diffusing compounds, a threshold for polarization was determined by measuring serum  
278 concentration at the time of symmetry breaking. We observed a strong variation between and within individual  
279 donors, however many cells proved sensitive to less than 10% serum concentration (Fig 5G). Since receptor  
280 saturation at high concentrations lowers the Chemotactic Index (as exemplified with  $\Delta\text{CCL21}$  in Fig 3D) and  
281 in the case of serum causes faster desensitization (Fig 4B) with an expected lower number of responding cells,  
282 we finally diluted the serum in culture medium and exposed cells to unsaturating gradients. The observed effect  
283 though was weaker, with only  $14 \pm 5\%$  polarizing cells (Fig 5C). Altogether, we conclude that under the same  
284 experimental conditions in which CCL21 triggers long-range chemotaxis of most cells, S1P-rich serum does  
285 not. Instead, serum is shortly chemokinetic on a small fraction of cells, while the transient polarization and  
286 lack of displacement of the remaining fraction of cells rather points towards a 'decision making' function.



**Fig 5. Serum triggers transient polarization and chemokinesis of a fraction of cells, but not chemotaxis.** (A) Cell polarization in single channels in the presence of the indicated serum concentrations. A total of 664 cells from 5 independently tested donors were imaged. (B) Time sequence and overlaid projections for bright field and inverted IRM imaging (green = adhesion patch) for a group of resensitized cells in 10% serum. (C) Quantification of cell polarization upon serum gradient arrival. 620 cells from 6 independently tested donors were exposed to pure serum (0 to 70% concentration range), while 395 cells from 3 independently tested donors were exposed to diluted serum (0 to 15% concentration range). (D) Time sequence and projections of 4 representative cells shortly polarizing upon serum arrival, but without net displacement. (E) Trajectories aligned in the origin and angle histogram for the cumulated 49 cells amenable for tracking. (F) From left to right, distribution of duration, displacement, and chemotactic index (C.I.) for those 49 tracks. As a comparison, same parameters for the 55 tracks shown in Fig 3B (CCL21 gradient, 1 representative donor) are plotted. (G) Threshold for cell polarization, defined as the serum concentration at the instant of symmetry breaking, for the 6 donors exposed to undiluted serum gradients. Values below 1% are plotted in a log scale. Each point in the dot blots represents one independently tested donor, except in (G) where they represent one cell. Scalebars = 10 $\mu$ m. \*\* indicate a p-value < 0.01 measured by multiple comparison ANOVA test.

287

288

289

290

291

292

293

294

295

296

297


298

299

300


301 **Instant stimulus arrival confirms naïve T lymphocyte transient polarization to serum**

302 Gradient experiments attained a maximum of only 21% responding cells (Fig 5C), as opposed to the global  
303 S1PR1 desensitization observed in flow cytometry (Fig 4D). Since in our device serum is gradually arriving  
304 by diffusion, we hypothesized that non-reacting cells may desensitize S1PR1 before reaching the threshold for  
305 a response. We therefore sought to instantly expose cells to serum as in Fig 5A, but with time-zero visualization  
306 and control. To achieve this, cells were captured on the substrate to prevent their flushing upon serum addition,  
307 in an 'open-well' setup to allow a fast stimulus arrival while recording cell behavior (Fig 6A). We used our  
308 optical micropatterning tool to generate an array of 240 circular capture spots coated with  $\alpha$ -CD45RA  
309 antibodies, to increase the experimental throughput while keeping a single-cell analysis and performed  
310 quantitative morphometry of cell contours to detect changes in their polarization state. When cells were first  
311 exposed to CCL21, we observed a fast and stable polarization of  $71 \pm 7\%$  cells, validating the method (Fig 6B  
312 and C). When the equivalent experiment was performed with serum, polarization was fast but transient, with  
313  $59 \pm 5\%$  and  $54 \pm 14\%$  polarized cells for 10% and 100% serum respectively, and no statistical difference as  
314 compared to CCL21 control (Fig 6B, C and Movie 9). Based on these data we conclude that fast exposure to  
315 serum transiently polarizes naïve T lymphocytes, providing a qualitative signal consistent with a 'decision  
316 making' function which is substantially different from the durable guiding signal triggered by CCL21 (Fig 7).




**Fig 6. Instant stimulus arrival confirms naïve T lymphocyte transient polarization to serum.** (A) Left side, cartoon exemplifying the ‘open-well’ experimental setup and the morphometric analysis used to score individual cell polarization states. Cells were considered polarized when their aspect ratio was higher than 1.2. Right side, low magnification bright-field image of a substrate after cell capture. Scalebar = 50  $\mu$ m. (B) Left side, high magnification bright-field images of cells from one representative donor at Time-zero, 3 and 16 minutes after the indicated stimulus arrival. Scalebar = 10  $\mu$ m. Right side, density scatter plots of cell aspect ratio as a function of time for each condition tested. Each dot corresponds to a single cell-contour and is colored according to the local density of events. Below, cell polarization as a function of time for the three datasets. Time-zero corresponds to the instant of stimulus addition. (C) Quantification of cell polarization during the whole acquisition period, values are higher than in (B) due to asynchronous cell response. Each condition was tested on 4 donors,  $n = 447, 652$  and  $440$  imaged cells for CCL21, 10% and 100% serum, respectively. n.s. = not significant (multiple comparison ANOVA test).

350



**Fig 7. Minimal mechanistic model for naïve T lymphocyte traffic in lymph nodes.** (A) Naïve T cells exit HEVs and migrate towards the central parenchyma guided by a long-range chemotaxis towards CCL21 (green). In the insert: Upon randomly encountering a cortical sinus, instant S1P sensing triggers the transmigration decision. Instead, S1PR1 *knock out* cells are retained in the parenchyma due to counteracting CCR7 signaling. Once in sinus, intermittent adhesion and S1PR1 desensitization can independently trigger flow-capture and lymph node exit through efferent lymphatics. (B) The alternative hypothesis of a short-range S1P gradient diffusing into the parenchyma barely changes the scenario. The position of the decision making is shifted from the lymphatic endothelium to a neighboring zone, where S1P is sensed.



379

### Supplementary Fig 1.

CCL21S6-Dy549P1 fluorescence intensity, measured in the same optic conditions as in Fig 3E and 3F, as a function of its surface concentration.

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395


396

397

398

399


**A**




### Supplementary Fig 2.

(A) Viability of cells from 6 independently tested donors after >6hs incubation without serum. Inset presents the live and dead conditions, scored by propidium iodide uptake (red cell). Scalebar = 10µm (B) Left and center, purified naïve T lymphocytes from 12 independently tested donors were fixed, stained for S1PR1, and the percent of S1PR1 positive cells was scored. The gray histogram corresponds to the isotype control used to define the gates. Right, S1PR1 expression vs time, for cells purified from 1 donor and incubated in the absence of serum for the indicated timepoints, then fixed and stained for S1PR1.

**B**







### Supplementary Fig 3.

Overlaid bright field and IRM projections for cells migrating in the presence of  $1\mu\text{M}$  CCL21 alone (-) or with 10% serum (+). Scalebar =  $20\mu\text{m}$ .

## Discussion

Naïve T lymphocyte recirculation through lymph nodes is a critical feature of the immune system at steady state condition. It is required for the vast repertoire of cells to screen for a cognate antigen-loaded dendritic cell, and it represents a crucial therapeutic target for various pathologies. CCL21 and S1P orchestrate this continuous trafficking, as deduced from perturbation experiments and *in vivo* imaging, and have been claimed chemotactic. However, to our knowledge no migration assay along a single and controlled gradient, coupled to *live* imaging, has been reported so far for naïve T lymphocytes. Here, we used customized *in vitro* setups to perform *live* imaging of human naïve T lymphocytes migrating under defined environmental conditions. By exposing cells to controlled and single stimuli, we revisited several dogmas in the field of lymphocyte migration and provided a quantitative directionality analysis for migrating naïve T lymphocytes.

We first demonstrated that, contrary to the literature<sup>14</sup>, CCL21 signals on naïve T lymphocytes not only when adsorbed but also in bulk solution. Because chemokine adsorption is based on electrostatic interactions, our assays do not discriminate whether those molecules are truly read from the substrate or slowly desorbing into a local soluble pool, in which case the substrate would only act as a chemokine depot. Future assays with a molecule faithfully bound to the substrate, such as through a biotinylated linker, should help answering this question. Regardless the mechanism under play, we verified the widely accepted haptokinesis and haptotaxis of naïve T lymphocytes in response to adsorbed CCL21, and we recorded their chemokinesis and chemotaxis in response to bulk CCL21, providing fine directionality analysis for both cases of taxis. Chemotactic indexes were higher for soluble gradients than adsorbed ones, despite the narrower range of experienced slopes in the

427 first case, indicating that soluble gradients may be more efficient at guiding cells. More generally, cell  
428 directivity proved in a similar range as that previously measured in response to CCL19<sup>19</sup>, but lower than that  
429 reported for dendritic cells migrating towards both CCR7 ligands<sup>53,54</sup>. Such values may reflect the importance  
430 of CCR7 guidance for antigen-loaded dendritic cells, for which a ballistic motion is needed to efficiently reach  
431 lymph nodes, whereas naïve T lymphocytes are gently attracted to areas of antigen presentation while keeping  
432 a screening behavior.

433 Our data also dismiss the reported lack of naïve T lymphocyte adhesion on ICAM-1<sup>14</sup>. By using IRM imaging,  
434 we proved that the speed of naïve T lymphocytes is modulated by intermittently adhering on ICAM-1. This is  
435 in line with *in vivo* data showing that LFA-1 is necessary to sustain fast migration in lymph nodes<sup>34,55</sup>.  
436 Interestingly, speed fluctuations were reported for migrating T lymphocytes in mouse lymph nodes<sup>15</sup>, and  
437 migration arrests were further correlated to intracellular calcium peaks *in vivo* and *in vitro*, at least for effector  
438 T lymphocytes in confined environments<sup>56</sup>. Given that human neutrophils also modulate their adhesion while  
439 migrating on ICAM-1 substrates<sup>44</sup>, it is tempting to speculate whether both cell types bear an internal clock  
440 controlling such adhesion runs, hence representing an intrinsic and intended feature. In the case of naïve T  
441 lymphocytes, perhaps to avoid excessive adhesion on ICAM-1-expressing dendritic cells and ensure antigen  
442 screening continuation. Simultaneous IRM and calcium imaging during *in vitro* migration should help  
443 answering this question. Finally, intermittent adhesion was not stabilized by an excess of bulk chemokine nor  
444 mild flow. A hypothesis is that stable adhesion under flow may be achieved by adding a selectin-mediated  
445 rolling step, in line with the long-established adhesion cascade for leukocyte transmigration through High  
446 Endothelial Venules (HEVs)<sup>57</sup>.

447 Finally, we analyzed the real-time response of naïve T lymphocytes to S1P-rich serum. After almost two  
448 decades of research, S1P biology remains a controversial topic with several standing models explaining  
449 lymphocyte exit from lymph nodes. Models claiming chemotaxis towards S1P are based on weak *in vitro*  
450 transmigration values, either due to premature exposure to suboptimal S1P concentrations and concomitant  
451 receptor desensitization, or lack of an appropriate carrier molecule. Here, by visualizing in real-time the cells'  
452 reaction to gradients of bioactive S1P, we observed two different behaviors: a small fraction of cells transiently  
453 polarizing and migrating, but with a short displacement and only a mild skew in directionality towards the  
454 serum source, and a bigger fraction of cells transiently polarizing on the spot and without displacement.  
455 Altogether, these data do not support the existence of efficient S1P-triggered chemotaxis, since under the same  
456 conditions in which CCL21 gradients triggered durable and long-range chemotaxis, serum factors, hence S1P,  
457 did not. Interestingly, because our gradients are built by gradually diffusing factors and likely also causing  
458 premature S1PR1 desensitization, these behaviors matched the reported values from Transwell assays: the  
459 observed 8% migrating cells recapitulate the transmigration values reported towards S1P alone<sup>4,30-34</sup>, while the

460 total 21% polarizing cells recapitulate the transmigration values reported towards S1P together with lymphatic  
461 endothelial cells (LECs)<sup>35</sup>. This correspondence suggested that cells polarizing in the spot represented a  
462 commitment to transmigrate through (and most likely aided by) LECs, and gave us the indication for an optimal  
463 S1P-sensing condition. Indeed, when cells were instantly exposed to serum the percent of polarizing cells  
464 increased to ~ 60%, to our knowledge the highest effect reported to date. Since migrating cells *in vivo* encounter  
465 cortical sinuses in an already polarized fashion, likely by CCR7 ligands, and since a similar effect was observed  
466 for 10% and 100% serum concentrations, we conclude serum factors provide naïve T lymphocytes with a  
467 qualitative ‘decision making’ signal, to trigger transmigration into cortical sinuses.

468 Taken together, our data complements *in vivo* observations and leads us to the following model of naïve T  
469 lymphocyte traffic (Fig. 7A). After accessing lymph nodes through HEVs or the subcapsular sinus floor, cells  
470 are gently attracted by long-range CCL19 and CCL21 gradients towards the central parenchyma. During this  
471 journey, they scan antigen-loaded dendritic cells, until randomly encountering a cortical sinus. Upon probing  
472 its lumen, S1PR1 is needed to achieve successful transmigration<sup>15</sup>. Since we did not observe any apparent  
473 serum-based inhibition of cell adhesion nor CCL21-triggered migration, the main role of S1P may be to force  
474 the transmigration step upon probing the cortical sinus lumen. Once in the lumen, intermittent adhesion and  
475 S1PR1 desensitization (followed by cell depolarization) can independently trigger the detachment of cells from  
476 LECs and their concomitant capture by the increasing flow of efferent lymph, which finally brings cells out of  
477 the lymph node and back into circulation. Our data does not exclude the possibility of a short-range S1P  
478 guidance (an order of magnitude lower than that of CCL21) in the vicinity of cortical sinuses (Fig. 7B). In such  
479 scenario the decision to exit may be taken upon gradient detection, a few body-lengths before reaching LECs,  
480 but the subsequent steps would remain the same. However, lack of *in vivo* evidence supporting a S1P gradient  
481 or chemotaxis towards sinuses, and rapid S1PR1 desensitization *in vitro* upon gradient sensing, often without  
482 displacement (Fig. 5), leads us to favor the first model. Finally, a potential stromal gate function of LECs is  
483 also not excluded, for instance by providing a scaffold for adhesion and transmigration or by delivering  
484 additional soluble or contact signals. Such notion is supported by the different, S1P-independent basal speed  
485 observed for cells migrating in the medullary cords as compared to those in the parenchyma<sup>33</sup>.

486 To conclude, *live* imaging in reductionist *in vitro* setups gave us a mechanistic understanding of naïve T  
487 lymphocyte traffic, complementing *in vivo* observations. Such insights may foster the development of more  
488 specific, tailored immunosuppressive drugs. Our study also paves the way for a consistent and quantitative  
489 characterization of human leukocyte migration. With a recent report on human B lymphocyte migration  
490 revealing differences with the mouse system<sup>42</sup>, this quest may become more relevant than previously thought.

491  
492 **Acknowledgments and funding**

493 We are grateful to the Cell Culture Platform facility (Luminy TPR2-INSERM), the Turing Centre for Living  
494 systems, the Regional Council of Provence-Alpes-Côte d’Azur and the LABEX INFORM program. Also the  
495 European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant  
496 agreement No713750; Agence Nationale de la Recherche, RECRUTE - ANR-15-CE15-0022 and ILIAAD  
497 ANR-18-CE09-0029; A\*MIDEX n° ANR- 11-IDEX-0001-02; and The Swiss National Science Foundation,  
498 grant number 310030\_189144.

499

#### 500 **Author contributions:**

501 NGS and OT designed the experiments, SS performed haptotaxis experiments, LDB and NGS performed  
502 serum-triggered polarization experiments, NGS performed all remaining experiments, NGS and SS wrote the  
503 scripts for analysis and analyzed the data, CM and MA produced the recombinant CCL21 variants under DFL’s  
504 supervision, NGS wrote the manuscript, all remaining authors revised it. NGS and OT supervised the project.

505

#### 506 **Ethics statement**

507 Human subjects: Blood from healthy volunteers was obtained through a formalized agreement with the French  
508 Blood Agency (Etablissement Français du Sang, agreement n° 2017-7222). Blood was obtained by the agency  
509 after informed consent of the donors, in accordance with the Declaration of Helsinki. All experiments were  
510 approved by the INSERM Institutional Review Board and ethics committee.

511

512 **Competing interests:** The authors declare no competing interests.

513

#### 514 **Materials and Methods**

##### 515 **Cells**

516 Whole blood from healthy adult donors of group 0, drawn into EDTA tubes, was obtained from the  
517 “Établissement Français du Sang”. Peripheral Blood Mononuclear Cells (PBMC) were recovered from the  
518 interface of a Ficoll gradient (Eurobio, Evry, France) and washed with Phosphate Buffer Saline (PBS, Gibco).  
519 Naïve T lymphocytes were purified with the Miltenyi naïve CD4+ T Cell Isolation Kit II. After purification,  
520 cells were kept in RPMI 1640 medium supplemented with penicillin 100 U/ml (Gibco, Carlsbad, CA),  
521 streptomycin 100 µg/ml (Gibco, Carlsbad, CA), 25 mM GlutaMax (Gibco, Carlsbad, CA), with or without  
522 10% fetal calf serum (FCS, Lonza, Basel, Switzerland) in a 37°C incubator with 5% CO<sub>2</sub>, until use. Human  
523 serum was prepared from the same donor, from blood coagulated in a dry tube. After 5 minutes centrifugation  
524 at 500 RCF the supernatant was taken, filtered through a 0.2 µm mesh and kept at 37°C until use.

## 525 **Flow cytometry**

526 One hundred thousand cells per condition were fixed for 10 minutes with 1% paraformaldehyde (PFA,  
527 Thermofisher), then washed once with 4 mL of FACS buffer (2% FCS in PBS), resuspended in 100  $\mu$ L and  
528 stained for 30 minutes at 4°C in the dark. They were finally washed with 4 mL FACS buffer and re-suspended  
529 in 0.5 mL to be analyzed in a LSR Fortessa X20 (BD Biosciences, Europe). For live staining, an equal number  
530 of purified cells or PBMCs were stained first on ice, then washed with FACS buffer and fixed with 1% PFA.  
531 For the blood sample, 200uL were first blocked with 1 mg human IgG (Tegeline, LFB Biomedicaments) for  
532 15 minutes on ice, immediately after stained for 30 minutes, erythrocytes were then lysed with RBC lysis  
533 buffer (eBioscience), finally cells were washed with 12 mL PBS and fixed with 1% PFA. The antibodies used  
534 for staining were APC/Cyanine7 anti-human CD45RA (clone HI100, Biolegend), PE anti-human CD197  
535 (CCR7, clone G043H7, Biolegend), PE/Cy7 anti-human CD62L (clone DREG-56, Biolegend), EF660 anti-  
536 human CD363 (S1PR1, clone SW4GYPP, eBioscience) and EF660 IGG1K isotype control (eBioscience).

## 537 **Devices**

538 Single channel devices consisted of Ibidi  $\mu$ -Slide uncoated IV 0.4 (Ibidi GMBH, Martinsreid, Germany).  
539 Surfaces were coated overnight at 4°C, either with 10  $\mu$ g/mL human ICAM-1 (R&D Systems), 1  $\mu$ g/mL CCL21  
540 (Miltenyi biotech) or a mixture of both, followed by blocking with 4% fatty acid-free Bovine Serum Albumin  
541 (BSA, Sigma) solution in PBS, for at least 15 min at room temperature. Devices were finally rinsed with PBS  
542 and then culture media. Flow experiments were performed in single channels connected to a pump system  
543 (neMESYS 290N, Cetoni). The gradient device was molded in PDMS and prepared as described elsewhere<sup>19</sup>,  
544 10 kDa Dextran FITC (Sigma) was used as a diffusion marker to analyze gradient dynamics. For CCL21  
545 surface micropatterning, CCL21-S6<sup>Dy549P1</sup> homogeneous substrates in single channels were UV-illuminated ( $\lambda$   
546 = 375 nm, 300s exposition at 5V) through a Digital Micromirror Device (Primo; Alveole) in the presence of  
547 photoinitiator (PLPP, Alveole), to degrade the chemokine in a modulated way. Patterns of interest were  
548 designed on Matlab (The MathWorks). The fluorescent intensity was calibrated into number of molecules by  
549 imaging serial dilutions in 39  $\mu$ m high PDMS microchannels, passivated with PEG-SVA to limit adsorption,  
550 as described elsewhere<sup>58</sup>. Substrates for cell capture were prepared on glass slides (Schott High performance  
551 coverslip 22x22#1.5H cleanroom cleaned) which were plasma activated (Harrick Plasma) during 30min and  
552 then incubated for 2 hours at 4°C with a 1% APTES 0.03% Acetic acid solution. Slides were then rinsed with  
553 Milli-Q water, dried and baked 15 min at 95°C. Open-wells (6x2mm) were finally created by sticking a 250 $\mu$ m-  
554 thick PDMS sticker on the slides. A solution of 23% mPEG-SVA (MW:5000 Da, INTERCHIM) 10mM  
555 NaHCO<sub>3</sub> was then added to the wells, and substrates were incubated overnight at 4°C. The next day they were  
556 rinsed with Milli-Q water, and 10 $\mu$ l of PLPP solution (Alveole) was added. Arrays of capture spots, 3 $\mu$ m in

557 radius, were illuminated with UV ( $\lambda=375\text{nm}$  for 180sec,  $\sim 2488\text{ mJ/mm}^2$  dose) through a Digital Micromirror  
558 Device (Primo™, Alvéole). Wells were rinsed with PBS and incubated overnight with 50  $\mu\text{g/mL}$  anti-human  
559 CD45RA antibody (Abcam ab212774, lot GR3365431-3), at 4°C.

## 560 **Recombinant chemokine expression**

561 pSUMO  $\Delta\text{CCL21}$  was cloned using the primers 5'-  
562 GGTGCTCGAGTCAGCCCTGGGCTGGTTTCTGTGGGGATGGTGTCTTG-3' and 5'-  
563 CCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGG-3' to amplify  $\Delta\text{CCL21}$   
564 from pSUMO CCL21<sup>26</sup> and introducing it into the pSUMO backbone using XbaI and XhoI cutting sites. The  
565 chemokines and dyes were produced as previously described<sup>46</sup>. In brief, S6-tagged CCL21 and  $\Delta\text{CCL21}$  were  
566 each produced in E.coli BL21 DE3, refolded and using a multi step protocol affinity purified, with a final C18  
567 reverse phase HPLC step. CoA-Dy549P1 was generated as described using DY-549P1-Maleimide (Dyomics  
568 GmbH, Germany) and CoA Li<sub>3</sub> (Sigma-Aldrich, Switzerland). CoA-Dy549P1 was transferred to CCL21-S6  
569 using the phosphopantetheinyl transferase Sfp and labelled chemokine purified using C18 reverse phase HPLC.

## 570 **Imaging and data analysis**

571 Experiments were performed on an inverted Zeiss Z1 automated microscope (Carl Zeiss, Germany) equipped  
572 with a CoolSnap HQ CCD camera (Photometrics) and piloted by  $\mu\text{Manager}$  1.4. Plan-Apochromat 10x/0.3 and  
573 20x/0.8 air objectives were used for bright-field imaging, while a 40x/1.3 oil one was used for Interference  
574 Reflection Microscopy (IRM). IRM images were first corrected by subtracting a background image, secondly  
575 the pixel values were inverted to convert dark signal into positive values, finally a rolling ball algorithm was  
576 applied to flatten the image. Cells were tracked using the FIJI plugin Trackmate<sup>59</sup>, except for serum  
577 experiments where the Manual Tracking plugin was used. Tracks were exported and further analysis and plots  
578 were performed with MATLAB custom-made scripts (MATLAB software, The MathWorks, Natick, MA,  
579 USA). The unbiased colormap for the heatmaps was taken from ref<sup>60</sup>. Gradient dynamics were analyzed with  
580 a custom-made FIJI macro, fluorescence intensity values were normalized with the equation:

$$581 \quad \frac{I - I_{min}}{I_{max} - I_{min}} \times [C]$$

582 Where  $I_{min}$  is the average value recorded on the sink channel (background),  $I_{max}$  is the average value recorded  
583 on the source channel, and [C] is the chemokine concentration applied at the source. Ilastik<sup>61</sup> was used for  
584 morphometric analysis, to create binary masks which were further processed with Fiji and analyzed with  
585 Matlab custom scripts.

## 586 **Statistical Analysis**

587 Multiple comparison ANOVA tests were used to compare datasets. The number of analyzed cells, tested donors  
588 and resulting *p*-values are specified on each figure's legend.

589

## 590 **References**

- 591 1. von Andrian, U. H. & Mempel, T. R. Homing and cellular traffic in lymph nodes. *Nat Rev Immunol* **3**, 867–878 (2003).
- 592 2. Schulz, O., Hammerschmidt, S. I., Moschovakis, G. L. & Förster, R. Chemokines and Chemokine Receptors in Lymphoid  
593 Tissue Dynamics. *Annu. Rev. Immunol.* **34**, 203–242 (2016).
- 594 3. Baeyens, A. A. L. & Schwab, S. R. Finding a Way Out: S1P Signaling and Immune Cell Migration. *Annu. Rev. Immunol.*  
595 **38**, 759–784 (2020).
- 596 4. Pham, T. H. M., Okada, T., Matloubian, M., Lo, C. G. & Cyster, J. G. S1P1 Receptor Signaling Overrides Retention  
597 Mediated by Gai-Coupled Receptors to Promote T Cell Egress. *Immunity* **28**, 122–133 (2008).
- 598 5. Tsai, H.-C. & Han, M. H. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in  
599 Autoimmunity and Inflammation. *Drugs* **76**, 1067–1079 (2016).
- 600 6. Maceyka, M., Harikumar, K. B., Milstien, S. & Spiegel, S. Sphingosine-1-phosphate signaling and its role in disease. *Trends*  
601 *in Cell Biology* **22**, 50–60 (2012).
- 602 7. Okada, T. *et al.* Antigen-Engaged B Cells Undergo Chemotaxis toward the T Zone and Form Motile Conjugates with Helper  
603 T Cells. *PLoS Biology* **3**, 15 (2005).
- 604 8. Ulvmar, M. H. *et al.* The atypical chemokine receptor CCRL1 shapes functional CCL21 gradients in lymph nodes. *Nat*  
605 *Immunol* **15**, 623–630 (2014).
- 606 9. Braun, A. *et al.* Afferent lymph-derived T cells and DCs use different chemokine receptor CCR7-dependent routes for  
607 entry into the lymph node and intranodal migration. *Nat Immunol* **12**, 879–887 (2011).
- 608 10. Rot, A. & von Andrian, U. H. Chemokines in innate and adaptive host defense: basic chemokines grammar for immune  
609 cells. *Annu Rev Immunol* **22**, 891–928 (2004).
- 610 11. Yang, B.-G. *et al.* Binding of Lymphoid Chemokines to Collagen IV That Accumulates in the Basal Lamina of High  
611 Endothelial Venules: Its Implications in Lymphocyte Trafficking. *J Immunol* **179**, 4376–4382 (2007).
- 612 12. de Paz, J. L. *et al.* Profiling Heparin–Chemokine Interactions Using Synthetic Tools. *ACS Chem. Biol.* **2**, 735–744 (2007).
- 613 13. Weber, M. *et al.* Interstitial Dendritic Cell Guidance by Haptotactic Chemokine Gradients. *Science* **339**, 328–332 (2013).
- 614 14. Woolf, E. *et al.* Lymph node chemokines promote sustained T lymphocyte motility without triggering stable integrin  
615 adhesiveness in the absence of shear forces. *Nat Immunol* **8**, 1076–1085 (2007).
- 616 15. Miller, M. J., Wei, S. H., Cahalan, M. D. & Parker, I. Autonomous T cell trafficking examined in vivo with intravital two-  
617 photon microscopy. *Proceedings of the National Academy of Sciences* **100**, 2604–2609 (2003).

- 618 16. Grigorova, I. L. *et al.* Cortical sinus probing, S1P 1 -dependent entry and flow-based capture of egressing T cells. *Nature*  
619 *Immunology* **10**, 58–65 (2009).
- 620 17. Okada, T. & Cyster, J. G. CC Chemokine Receptor 7 Contributes to Gi-Dependent T Cell Motility in the Lymph Node. *The*  
621 *Journal of Immunology* **178**, 2973–2978 (2007).
- 622 18. Worbs, T., Mempel, T. R., Bölter, J., von Andrian, U. H. & Förster, R. CCR7 ligands stimulate the intranodal motility of T  
623 lymphocytes in vivo. *The Journal of Experimental Medicine* **204**, 489–495 (2007).
- 624 19. Garcia-Seyda, N. *et al.* Microfluidic device to study flow-free chemotaxis of swimming cells. *Lab Chip* (2020)  
625 doi:10.1039/D0LC00045K.
- 626 20. Jørgensen, A. S. *et al.* CCL19 with CCL21-tail displays enhanced glycosaminoglycan binding with retained chemotactic  
627 potency in dendritic cells. *J Leukoc Biol* **104**, 401–411 (2018).
- 628 21. Luther, S. A., Tang, H. L., Hyman, P. L., Farr, A. G. & Cyster, J. G. Coexpression of the chemokines ELC and SLC by T  
629 zone stromal cells and deletion of the ELC gene in the plt/plt mouse. *Proceedings of the National Academy of Sciences* **97**, 12694–  
630 12699 (2000).
- 631 22. Link, A. *et al.* Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells. *Nat Immunol* **8**, 1255–  
632 1265 (2007).
- 633 23. Miller, H. *et al.* High-Speed Single-Molecule Tracking of CXCL13 in the B-Follicle. *Front. Immunol.* **9**, (2018).
- 634 24. Cosgrove, J. *et al.* B cell zone reticular cell microenvironments shape CXCL13 gradient formation. *Nat Commun* **11**, 3677  
635 (2020).
- 636 25. Schumann, K. *et al.* Immobilized Chemokine Fields and Soluble Chemokine Gradients Cooperatively Shape Migration  
637 Patterns of Dendritic Cells. *Immunity* **32**, 703–713 (2010).
- 638 26. Hauser, M. A. *et al.* Distinct CCR7 glycosylation pattern shapes receptor signaling and endocytosis to modulate chemotactic  
639 responses. *Journal of Leukocyte Biology* **99**, 993–1007 (2016).
- 640 27. Graham, G. J., Handel, T. M. & Proudfoot, A. E. I. Leukocyte Adhesion: Reconceptualizing Chemokine Presentation by  
641 Glycosaminoglycans. *Trends in Immunology* **40**, 472–481 (2019).
- 642 28. Ramos-Perez, W. D., Fang, V., Escalante-Alcalde, D., Cammer, M. & Schwab, S. R. A map of the distribution of  
643 sphingosine 1-phosphate in the spleen. *Nat Immunol* **16**, 1245–1252 (2015).
- 644 29. Fang, V. *et al.* Gradients of the signaling lipid S1P in lymph nodes position natural killer cells and regulate their interferon-  
645  $\gamma$  response. *Nat Immunol* **18**, 15–25 (2017).
- 646 30. Arnon, T. I. *et al.* GRK2-Dependent S1PR1 Desensitization Is Required for Lymphocytes to Overcome Their Attraction to  
647 Blood. *Science* **333**, 1898–1903 (2011).
- 648 31. Matloubian, M. *et al.* Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1.  
649 *Nature* **427**, 355–360 (2004).



- 650 32. Schwab, S. R. Lymphocyte Sequestration Through S1P Lyase Inhibition and Disruption of S1P Gradients. *Science* **309**,  
651 1735–1739 (2005).
- 652 33. Drouillard, A. *et al.* Human Naive and Memory T Cells Display Opposite Migratory Responses to Sphingosine-1 Phosphate.  
653 *J.I.* **200**, 551–557 (2018).
- 654 34. Reichardt, P. *et al.* A role for LFA-1 in delaying T-lymphocyte egress from lymph nodes. *EMBO J* **32**, 829–843 (2013).
- 655 35. Xiong, Y. *et al.* CD4 T cell sphingosine 1-phosphate receptor (S1PR)1 and S1PR4 and endothelial S1PR2 regulate afferent  
656 lymphatic migration. *Sci. Immunol.* **4**, eaav1263 (2019).
- 657 36. Graeler, M., Shankar, G. & Goetzl, E. J. Cutting Edge: Suppression of T Cell Chemotaxis by Sphingosine 1-Phosphate. *J*  
658 *Immunol* **169**, 4084–4087 (2002).
- 659 37. Ledgerwood, L. G. *et al.* The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral  
660 tissue T lymphocytes into afferent lymphatics. *Nat Immunol* **9**, 42–53 (2008).
- 661 38. Wei, S. H. *et al.* Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells  
662 to lymphatic sinuses. *Nat Immunol* **6**, 1228–1235 (2005).
- 663 39. Aoun, L. *et al.* Leukocyte transmigration and longitudinal forward-thrusting force in a microfluidic Transwell device.  
664 *Biophys J* **120**, 2205–2221 (2021).
- 665 40. Davis, M. M. A Prescription for Human Immunology. *Immunity* **29**, 835–838 (2008).
- 666 41. Pulendran, B. & Davis, M. M. The science and medicine of human immunology. 13 (2020).
- 667 42. Park, S. M. *et al.* Migratory cues controlling B-lymphocyte trafficking in human lymph nodes. *Immunology & Cell Biology*  
668 **99**, 49–64 (2021).
- 669 43. Aoun, L. *et al.* Amoeboid Swimming Is Propelled by Molecular Paddling in Lymphocytes. *Biophysical Journal* (2020)  
670 doi:10.1016/j.bpj.2020.07.033.
- 671 44. Garcia-Seyda, N. *et al.* Human neutrophils swim and phagocytise bacteria. *Biology of the Cell* **113**, 28–38 (2021).
- 672 45. Barry, N. P. & Bretscher, M. S. Dictyostelium amoebae and neutrophils can swim. *Proceedings of the National Academy*  
673 *of Sciences* **107**, 11376–11380 (2010).
- 674 46. Artinger, M., Matti, C., Gerken, O. J., Veldkamp, C. T. & Legler, D. F. A Versatile Toolkit for Semi-Automated Production  
675 of Fluorescent Chemokines to Study CCR7 Expression and Functions. *International Journal of Molecular Sciences* **22**, 4158 (2021).
- 676 47. Luo, X. *et al.* Lymphocytes perform reverse adhesive haptotaxis mediated by LFA-1 integrins. *J Cell Sci* **133**, (2020).
- 677 48. Strale, P.-O. *et al.* Multiprotein Printing by Light-Induced Molecular Adsorption. *Adv. Mater.* **28**, 2024–2029 (2016).
- 678 49. Christoffersen, C. *et al.* Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M.  
679 *PNAS* **108**, 9613–9618 (2011).
- 680 50. Blaho, V. A. *et al.* HDL-bound sphingosine-1-phosphate restrains lymphopoiesis and neuroinflammation. *Nature* **523**, 342–  
681 346 (2015).

- 682 51. Schwab, S. R. *et al.* Lymphocyte Sequestration Through S1P Lyase Inhibition and Disruption of S1P Gradients. *Science*  
683 **309**, 1735–1739 (2005).
- 684 52. Lo, C. G., Xu, Y., Proia, R. L. & Cyster, J. G. Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression  
685 during lymphocyte recirculation and relationship to lymphoid organ transit. *Journal of Experimental Medicine* **201**, 291–301 (2005).
- 686 53. Aizel, K. *et al.* A tuneable microfluidic system for long duration chemotaxis experiments in a 3D collagen matrix. *Lab Chip*  
687 **17**, 3851–3861 (2017).
- 688 54. Vargas, P. *et al.* Innate control of actin nucleation determines two distinct migration behaviours in dendritic cells. *Nat Cell*  
689 *Biol* **18**, 43–53 (2016).
- 690 55. Katakai, T., Habiro, K. & Kinashi, T. Dendritic Cells Regulate High-Speed Interstitial T Cell Migration in the Lymph Node  
691 via LFA-1/ICAM-1. *J.I.* **191**, 1188–1199 (2013).
- 692 56. Dong, T. X. *et al.* Intermittent Ca<sup>2+</sup> signals mediated by Orai1 regulate basal T cell motility. *eLife* **6**, e27827 (2017).
- 693 57. Zhou, F. *et al.* The kinetics of E-selectin- and P-selectin-induced intermediate activation of integrin  $\alpha$ L $\beta$ 2 on neutrophils.  
694 *Journal of Cell Science* **134**, jcs258046 (2021).
- 695 58. Robert, P. *et al.* Functional Mapping of Adhesiveness on Live Cells Reveals How Guidance Phenotypes Can Emerge From  
696 Complex Spatiotemporal Integrin Regulation. *Front. Bioeng. Biotechnol.* **9**, 625366 (2021).
- 697 59. Tinevez, J.-Y. *et al.* TrackMate: An open and extensible platform for single-particle tracking. *Methods* **115**, 80–90 (2017).
- 698 60. Crameri, F., Shephard, G. E. & Heron, P. J. The misuse of colour in science communication. *Nature Communications* **11**,  
699 5444 (2020).
- 700 61. Berg, S. *et al.* ilastik: interactive machine learning for (bio)image analysis. *Nat Methods* **16**, 1226–1232 (2019).
- 701